Electromed, Inc. (ELMD): Price and Financial Metrics


Electromed, Inc. (ELMD): $10.11

-0.79 (-7.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ELMD Stock Summary

  • ELMD's current price/earnings ratio is 42.95, which is higher than 86.98% of US stocks with positive earnings.
  • For ELMD, its debt to operating expenses ratio is greater than that reported by only 0.42% of US equities we're observing.
  • ELMD's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 11.81% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ELECTROMED INC are GOLF, SWBI, TGEN, OESX, and UTMD.
  • Visit ELMD's SEC page to see the company's official filings. To visit the company's web site, go to www.smartvest.com.

ELMD Valuation Summary

  • ELMD's price/sales ratio is 2.2; this is 0% higher than that of the median Healthcare stock.
  • Over the past 147 months, ELMD's price/sales ratio has gone down 0.1.

Below are key valuation metrics over time for ELMD.

Stock Date P/S P/B P/E EV/EBIT
ELMD 2022-09-09 2.2 2.7 40.7 28.5
ELMD 2022-09-08 2.1 2.5 37.4 26.0
ELMD 2022-09-07 2.0 2.5 36.4 25.2
ELMD 2022-09-06 2.0 2.4 35.7 24.7
ELMD 2022-09-02 1.9 2.3 34.0 23.4
ELMD 2022-09-01 1.9 2.3 34.0 23.4

ELMD Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at 15.99%.
  • Its 2 year revenue growth rate is now at 16.56%.
  • Its 5 year cash and equivalents growth rate is now at 159.76%.
ELMD's revenue has moved up $18,122,827 over the prior 70 months.

The table below shows ELMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 41.659 -0.686 2.305
2022-03-31 39.85878 0.805168 2.32154
2021-12-31 38.50476 1.480121 1.900311
2021-09-30 37.75283 1.67905 2.265738
2021-06-30 35.756 3.077 2.362
2021-03-31 33.16457 3.608987 3.271013

ELMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ELMD has a Quality Grade of A, ranking ahead of 95.51% of graded US stocks.
  • ELMD's asset turnover comes in at 0.99 -- ranking 21st of 183 Medical Equipment stocks.
  • DYNT, SYK, and IRMD are the stocks whose asset turnover ratios are most correlated with ELMD.

The table below shows ELMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.990 0.764 0.161
2021-03-31 0.943 0.783 0.196
2020-12-31 0.971 0.781 0.234
2020-09-30 0.974 0.777 0.239
2020-06-30 1.015 0.776 0.279
2020-03-31 1.102 0.768 0.301

ELMD Stock Price Chart Interactive Chart >

Price chart for ELMD

ELMD Price/Volume Stats

Current price $10.11 52-week high $13.46
Prev. close $10.90 52-week low $8.75
Day low $10.05 Volume 31,400
Day high $10.80 Avg. volume 10,774
50-day MA $9.86 Dividend yield N/A
200-day MA $11.51 Market Cap 85.68M

Electromed, Inc. (ELMD) Company Bio


Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of all ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was founded in 1992 and is headquartered in New Prague, Minnesota.


ELMD Latest News Stream


Event/Time News Detail
Loading, please wait...

ELMD Latest Social Stream


Loading social stream, please wait...

View Full ELMD Social Stream

Latest ELMD News From Around the Web

Below are the latest news stories about ELECTROMED INC that investors may wish to consider to help them evaluate ELMD as an investment opportunity.

Electromed, Inc. Announces Fiscal 2022 Fourth Quarter and Full Year Financial Results

NEW PRAGUE, Minn., August 23, 2022--Electromed, Inc. Announces Fiscal 2022 Fourth Quarter and Full Year Financial Results

Yahoo | August 23, 2022

Electromed, Inc. Schedules its Fourth Quarter and Fiscal 2022 Financial Results Conference Call for August 23, 2022 at 5:00 p.m. ET

NEW PRAGUE, Minn., August 02, 2022--Electromed, Inc. Schedules its Fourth Quarter and Fiscal 2022 Financial Results Conference Call for August 23, 2022 at 5:00 p.m. ET

Yahoo | August 2, 2022

Electromed, Inc. Announces Election of Andrew Summers as Additional Independent Director

NEW PRAGUE, Minn., July 25, 2022--Electromed, Inc. ("Electromed") (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it has elected a new independent director, Andrew Summers, to its Board of Directors, effective July 25, 2022. In connection with the election, Electromed has entered into a new cooperation agreement with Summers Value Partners LLC ("Summers Value Partners"), an investment firm that beneficially owns approximately 6.1% of Electromed’s

Yahoo | July 25, 2022

Electromed, Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference

NEW PRAGUE, Minn., July 19, 2022--Electromed, Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference

Yahoo | July 19, 2022

Electromed, Inc. Announces Clinical Abstract Poster at ATS Conference: Bronchiectasis Patients Showed Improved Outcomes and Reduction in Healthcare Resource Utilization When Using HFCWO Therapy

NEW PRAGUE, Minn., May 19, 2022--Electromed, Inc. (NYSE American: ELMD) today announced the results of a third-party, clinical study presented as a clinical abstract poster at the American Thoracic Society International Conference in San Francisco, CA. The study’s key findings reveal that patients who used high frequency chest wall oscillation ("HFCWO") therapy experienced an improvement in health outcomes, as well as a reduction in healthcare resource utilization ("HCRU"), including a reduction

Yahoo | May 19, 2022

Read More 'ELMD' Stories Here

ELMD Price Returns

1-mo 1.51%
3-mo -1.94%
6-mo -20.71%
1-year -15.11%
3-year 49.56%
5-year 42.19%
YTD -22.23%
2021 32.52%
2020 13.41%
2019 69.94%
2018 -16.14%
2017 56.44%

Continue Researching ELMD

Want to see what other sources are saying about Electromed Inc's financials and stock price? Try the links below:

Electromed Inc (ELMD) Stock Price | Nasdaq
Electromed Inc (ELMD) Stock Quote, History and News - Yahoo Finance
Electromed Inc (ELMD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5717 seconds.